Efficacy and Underlying Mechanism of Berberine Against Atherosclerosis: A Meta-Analysis in Preclinical Animal Studies

被引:2
作者
Jia, Dongdong [1 ]
Zhang, XinYue [1 ]
Guo, Qianqian [1 ]
Yang, Rui [1 ]
Yu, Haitao [2 ]
Zhao, Mengzhu [1 ]
Shi, Liu [1 ]
Liu, Menghua [1 ]
Wu, Aiming [1 ]
Zhang, Dongmei [1 ]
机构
[1] Beijing Univ Chinese Med, Dongzhimen Hosp, Key Lab Chinese Internal Med, Minist Educ & Beijing, Beijing 100700, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pathophysiol,Key Lab,Minist Educ Neurol Diso, Wuhan, Peoples R China
关键词
Berberine; atherosclerosis; preclinical studies; meta-analysis; mechanisms; CHOLESTEROL; HDL; COMPLEMENT; EXPRESSION; PREVENTION; MODELS; GUT;
D O I
10.1097/FJC.0000000000001308
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerosis is the primary cause of many cardiovascular diseases, and an increasing number of studies have shown that berberine could delay plaque formation and development. Therefore, we aimed to evaluate its effects and explore its mechanisms in this meta-analysis. We searched PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang, and VIP databases for original preclinical studies to conduct meta-analysis. Twelve articles (16 studies; 312 ApoE(-/-) mice) were included, and all the studies scored 3-5 points according to SYRCLE's risk of bias tool. Berberine could significantly decrease plaque area and plaque macrophage content (plaque area, SMD = -2.02, 95% CI: -2.80 to -1.24, P = 0.000; plaque macrophage content, SMD = -4.28, 95% CI: -7.67 to -0.88, P = 0.013); lower the levels of TC, triglyceride, and low-density lipoprotein (TC, SMD = -1.47, 95% CI: -2.20 to -0.74, P = 0.000; triglyceride, SMD = -0.77, 95% CI: -1.21 to -0.33, P = 0.000; low-density lipoprotein, SMD = -0.61, 95% CI: -1.11 to -0.11, P = 0.000), and change the secretion of inflammatory cytokines (IL-1 beta, SMD = -2.29, 95% CI: -3.40 to -1.18, P = 0.000; interleukin-6, SMD = -1.48, 95% CI: -2.11 to -0.85, P = 0.008; tumor necrosis factor-alpha, SMD = -1.98, 95% CI: -3.01 to -0.94, P = 0.000; interleukin-10, SMD = 1.78, 95% CI: 0.76 to 2.80, P = 0.015), but there were no significant differences in high-density lipoprotein levels and plaque lipid content (high-density lipoprotein, SMD = 0.02, 95% CI: -0.35 to 0.40, P = 0.021; plaque lipid content, SMD = -6.85, 95% CI: -21.09 to 7.39, P = 0.007). The results were robust across a range of sensitivity analyses. Therefore, the results indicate that berberine is a promising drug for the treatment of atherosclerosis through regulating lipid metabolism, inflammation, and plaque composition. However, some potential mechanisms remain to be further elucidated.
引用
收藏
页码:476 / 488
页数:13
相关论文
共 54 条
[1]   A New Therapeutic Candidate for Cardiovascular Diseases: Berberine [J].
Cai, Yun ;
Xin, Qiqi ;
Lu, Jinjin ;
Miao, Yu ;
Lin, Qian ;
Cong, Weihong ;
Chen, Keji .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[2]   Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE-/- mice [J].
Chen, Junwen ;
Cao, Jiatian ;
Fang, Lu ;
Liu, Bo ;
Zhou, Qing ;
Sun, Yinggang ;
Wang, Yue ;
Li, Yigang ;
Meng, Shu .
JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
[3]   Promising Anti-atherosclerotic Effect of Berberine: Evidence from In Vitro, In Vivo, and Clinical Studies [J].
Fatahian, Alireza ;
Haftcheshmeh, Saeed Mohammadian ;
Azhdari, Sara ;
Farshchi, Helaleh Kaboli ;
Nikfar, Banafsheh ;
Momtazi-Borojeni, Amir Abbas .
REVIEWS OF PHYSIOLOGY, BIOCHEMISTRY AND PHARMACOLOGY, VOL 178, 2020, 178 :83-110
[4]   Comparative effect of berberine and its derivative 8-cetylberberine on attenuating atherosclerosis in ApoE-/- mice [J].
Feng, Min ;
Zou, Zongyao ;
Zhou, Xia ;
Hu, Yinran ;
Ma, Hang ;
Xiao, Yubo ;
Li, Xuegang ;
Ye, Xiaoli .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2017, 43 :195-202
[5]   Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel [J].
Ference, Brian A. ;
Ginsberg, Henry N. ;
Graham, Ian ;
Ray, Kausik K. ;
Packard, Chris J. ;
Bruckert, Eric ;
Hegele, Robert A. ;
Krauss, Ronald M. ;
Raal, Frederick J. ;
Schunkert, Heribert ;
Watts, Gerald F. ;
Boren, Jan ;
Fazio, Sergio ;
Horton, Jay D. ;
Masana, Luis ;
Nicholls, Stephen J. ;
Nordestgaard, Borge G. ;
van de Sluis, Bart ;
Taskinen, Marja-Riitta ;
Tokgozoglu, Lale ;
Landmesser, Ulf ;
Laufs, Ulrich ;
Wiklund, Olov ;
Stock, Jane K. ;
Chapman, M. John ;
Catapano, Alberico L. .
EUROPEAN HEART JOURNAL, 2017, 38 (32) :2459-2472
[6]   Colchicine for secondary prevention in coronary disease [J].
Fiolet, Aernoud T. L. ;
Nidorf, S. Mark ;
Cornel, Jan H. .
EUROPEAN HEART JOURNAL, 2021, 42 (11) :1060-1061
[7]   Is a High HDL-Cholesterol Level Always Beneficial? [J].
Franczyk, Beata ;
Rysz, Jacek ;
Lawinski, Janusz ;
Rysz-Gorzynska, Magdalena ;
Gluba-Brzozka, Anna .
BIOMEDICINES, 2021, 9 (09)
[8]  
GBD 2016 Causes of Death Collaborators, 2017, LANCET, V390, P1151, DOI [DOI 10.1016/S0140-6736, DOI 10.1016/S0140-6736(17)32152-9, 10.1016/s0140-6736(17)32152-9]
[9]   A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification [J].
Goettsch, Claudia ;
Hutcheson, Joshua D. ;
Hagita, Sumihiko ;
Rogers, Maximillian A. ;
Creager, Michael D. ;
Tan Pham ;
Choi, Jung ;
Mlynarchik, Andrew K. ;
Pieper, Brett ;
Kjolby, Mads ;
Aikawa, Masanori ;
Aikawa, Elena .
ATHEROSCLEROSIS, 2016, 251 :109-118
[10]   The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [J].
Guo, Jing ;
Chen, Hongdong ;
Zhang, Xueqin ;
Lou, Wenjiao ;
Zhang, Pingna ;
Qiu, Yuheng ;
Zhang, Chao ;
Wang, Yaoxian ;
Liu, Wei Jing .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2021, 2021